Favorable outcomes after single cord blood transplantation for patients with high-risk hematological diseases; a single institute retrospective analysis

Hematopoietic stem cell transplantation (HSCT) is a potentially curative strategy for a wide variety of hematological diseases. With the expansion of donor sources, unrelated cord blood (UCB) and haploidentical transplantations, especially those with post-transplant cyclophosphamide (Haplo-PTCY), have been used as alternatives when matched sibling donors (MSDs) and matched unrelated donors (MUDs) are unavailable1, 2. In particular, UCB has become an established source for HSCT because of its widespread availability, rapid accessibility, increased tolerance to human leukocyte antigen (HLA) mismatches, and decreased incidence of chronic graft-versus-host disease (GVHD)3.

Source: Biology of Blood and Marrow Transplantation - February 25, 2021 Category: Hematology Authors: Fumiya Wada, Junya Kanda, Mizuki Watanabe, Yasuyuki Arai, Masakatsu Hishizawa, Tadakazu Kondo, Kouhei Yamashita, Akifumi Takaori-Kondo Source Type: research